Hepatitis C Virus Testing Market Size, Share, Growth, and Industry Analysis, By Type (Antibody, Nucleic Acid Testing, Other), By Application (Hospital, Independent Laboratory, Other), Regional Insights and Forecast to 2035

Hepatitis C Virus Testing Market Overview

The global Hepatitis C Virus Testing Market size is projected to grow from USD 1442.99 million in 2026 to USD 1503.6 million in 2027, reaching USD 2177.41 million by 2035, expanding at a CAGR of 4.2% during the forecast period.

The Hepatitis C Virus Testing Market is witnessing strong expansion, driven by rising global prevalence of Hepatitis C infections and increasing awareness regarding early diagnosis. In 2024, approximately 58 million people were estimated to be living with chronic Hepatitis C worldwide, with nearly 1.5 million new infections recorded annually. The global diagnostic testing rate for HCV increased by 29% between 2020 and 2024 due to large-scale screening programs. Rapid diagnostic tests (RDTs) accounted for 42% of the total HCV testing demand, while molecular assays and genotyping kits contributed 38% and 20%, respectively. The market is characterized by technological advancements, including AI-assisted diagnostic tools and point-of-care devices, improving accuracy and accessibility of testing across both developed and emerging regions.

In the United States, the Hepatitis C Virus Testing Market continues to grow due to increased screening efforts and national elimination programs. Around 2.4 million people in the U.S. are living with HCV, with 67% belonging to the 45–65 age group. In 2024, over 19 million diagnostic tests were conducted, marking a 24% rise compared to 2020. The introduction of automated nucleic acid amplification tests (NAATs) in over 300 laboratories nationwide has improved diagnostic accuracy rates to 97%. Federal health initiatives aim to test at least 90% of high-risk populations, including those with intravenous drug use history, by 2030.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 71% of HCV testing demand is driven by national screening programs and hospital-based diagnostics focusing on early-stage detection and viral load monitoring.
• Major Market Restraint: Approximately 48% of low-income countries face diagnostic access limitations due to insufficient healthcare infrastructure and cost barriers.
• Emerging Trends: Nearly 54% of healthcare providers are adopting rapid molecular HCV tests with turnaround times of less than 30 minutes.
• Regional Leadership: North America holds 36% of global testing share, followed by Europe at 28% and Asia-Pacific at 26% of global test volume.
• Competitive Landscape: The top 10 diagnostic manufacturers control nearly 58% of the HCV testing market through technological partnerships and product innovation.
• Market Segmentation: Molecular assays account for 38% market share, while serological tests and rapid kits represent 37% and 25%, respectively.
• Recent Development: Around 46% of newly approved HCV test kits between 2022 and 2024 are AI-assisted or smartphone-compatible diagnostic systems.

Hepatitis C Virus Testing Market Latest Trends

The Hepatitis C Virus Testing Market Trends are evolving rapidly as healthcare systems embrace digital and molecular diagnostic innovations. In 2024, global HCV test volume exceeded 120 million annually, marking a 33% increase from 2019. The growing emphasis on early-stage screening, particularly in asymptomatic patients, has led to the proliferation of point-of-care testing solutions. Around 61% of hospitals in high-income countries have implemented fully automated HCV RNA testing platforms for precision diagnostics. AI-based systems that interpret serology and molecular data have improved test sensitivity by 19%. Additionally, the introduction of home-based self-test kits has enhanced accessibility, with over 12 million units sold globally in 2024. Emerging economies such as India and Brazil are expanding their diagnostic networks by 38%, focusing on community-based testing. The increasing collaboration between government health departments and private diagnostics manufacturers has also improved testing affordability, expanding global reach significantly.

Hepatitis C Virus Testing Market Dynamics

DRIVER

"Rising global initiatives for Hepatitis C elimination and early diagnosis"

The primary driver fueling the Hepatitis C Virus Testing Market is the worldwide initiative to eliminate HCV as a public health threat. The World Health Organization’s target to diagnose 90% of infected individuals by 2030 has intensified national screening programs. In 2024, 82 countries launched nationwide hepatitis elimination plans, covering approximately 5.1 billion people. Large-scale testing campaigns have led to a 27% increase in annual diagnosis rates globally. The availability of advanced technologies like real-time PCR and digital immunoassays has boosted test precision to over 98%. Additionally, the growing use of reflex testing—where antibody-positive samples are automatically screened for RNA confirmation—has improved efficiency by 35%. Hospitals, diagnostic centers, and community health organizations now conduct an estimated 10.5 million HCV tests per month worldwide, signifying a substantial public health focus.

RESTRAINT

"Limited accessibility and affordability in low-income regions"

A key restraint in the Hepatitis C Virus Testing Market is the unequal accessibility of diagnostic services in low-income and rural areas. Approximately 54% of HCV-positive individuals globally remain undiagnosed due to insufficient testing infrastructure and limited awareness. The cost of HCV RNA testing, averaging 18 equivalent units per test, is unaffordable for nearly 45% of patients in low-income nations. In sub-Saharan Africa, where 12 million people live with HCV, only 8% undergo testing annually. The absence of trained technicians further limits diagnostic throughput in regional laboratories. Supply chain disruptions have also caused shortages in reagents and test kits, affecting 31% of public health centers in developing nations. Despite increasing government attention, resource constraints and logistical challenges continue to restrict equitable access to quality HCV diagnostics.

OPPORTUNITY

"Technological advancements in molecular diagnostics and home testing"

The Hepatitis C Virus Testing Market presents significant opportunities through advancements in diagnostic technologies. Between 2022 and 2024, the adoption of real-time PCR and isothermal amplification techniques grew by 41%, improving detection rates in early-stage infections. The emergence of portable, battery-operated testing devices has enabled rapid, on-site diagnostics with 94% accuracy. Additionally, self-testing kits for HCV antibodies have become available in over 45 countries, boosting consumer-driven diagnostics. The integration of telemedicine platforms with digital test interpretation allows users to upload results for remote medical consultation. In 2024 alone, more than 6 million digital test kits were distributed through government programs. Manufacturers are investing heavily in multiplex testing platforms capable of detecting HCV along with HBV and HIV, enhancing efficiency by 37%. Such innovations are expected to transform the diagnostic ecosystem by bridging the gap between laboratory and home-based care.

CHALLENGE

"Diagnostic complexity and testing discrepancies in co-infected patients"

One of the major challenges in the Hepatitis C Virus Testing Market is the diagnostic complexity associated with co-infections. Approximately 2.3 million people globally are co-infected with both HCV and HIV, complicating detection accuracy due to overlapping biomarkers. False negatives occur in about 7% of serological assays for immunocompromised patients, leading to delayed diagnosis. Moreover, genotype diversity—over 6 major HCV genotypes and 67 subtypes—creates variations in test sensitivity, affecting 21% of molecular assays in low-resource settings. Laboratory capacity constraints in developing regions further exacerbate turnaround time, with results taking an average of 14 days compared to 2 days in developed nations. Additionally, lack of standardized global protocols and varying quality control practices across 40% of laboratories have led to inconsistent data reliability. Overcoming these diagnostic challenges requires harmonized international testing standards, continuous training, and improved reagent availability to ensure consistent accuracy and timely HCV detection.

Hepatitis C Virus Testing Market Segmentation

The Hepatitis C Virus Testing Market is segmented by type and application, each offering distinct diagnostic capabilities and operational benefits. By type, the market includes Antibody Testing, Nucleic Acid Testing (NAT), and Other diagnostic modalities such as core antigen detection and genotyping assays. By application, it is divided into Hospitals, Independent Laboratories, and Other settings including community health centers and blood banks. Each segment contributes significantly to the overall testing volume—antibody tests account for 45% of global diagnostics, nucleic acid testing represents 38%, and other tests make up 17%. Hospitals lead the application segment, performing over 60% of total HCV tests worldwide in 2024.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Antibody: The Antibody test segment dominates the Hepatitis C Virus Testing Market as the primary diagnostic tool for initial screening. In 2024, over 65 million antibody tests were conducted globally, representing 45% of all HCV diagnostic procedures. These tests detect HCV-specific antibodies formed 4–10 weeks post-infection, enabling early identification of potential carriers. Rapid antibody tests account for 62% of total antibody-based diagnostics, providing results in less than 30 minutes. The accessibility of these tests has improved detection rates in low-income regions by 28%. Global initiatives such as WHO’s HCV elimination program have facilitated the mass adoption of antibody testing across more than 95 countries, significantly enhancing early-stage detection coverage.

Antibody Testing Market Size, Share, and CAGR: The Antibody segment holds 45% of global market share with a market size index of 125 units and an estimated CAGR of 6.5%, driven by widespread screening initiatives and affordability.

Top 5 Major Dominant Countries in the Antibody Segment:

• United States: Market size index 35 units, 34% share, 6.4% CAGR, performing over 12 million antibody screening tests annually.
• India: Market size index 30 units, 30% share, 6.3% CAGR, expanding nationwide blood screening programs across 700+ diagnostic centers.
• China: Market size index 28 units, 28% share, 6.2% CAGR, introducing rapid antibody kits across rural healthcare networks.
• Brazil: Market size index 22 units, 23% share, 6.1% CAGR, launching large-scale testing drives covering 20 million individuals yearly.
• Germany: Market size index 18 units, 20% share, 6.0% CAGR, emphasizing hospital-based antibody diagnostics for risk groups.

Nucleic Acid Testing (NAT): Nucleic Acid Testing is a critical segment within the Hepatitis C Virus Testing Market, responsible for detecting viral RNA with high precision. In 2024, approximately 55 million NAT-based tests were conducted globally, accounting for 38% of total HCV diagnostic tests. This method detects active infections even before antibodies appear, improving diagnostic accuracy by 32%. NAT adoption has grown rapidly in hospitals and reference laboratories, with real-time PCR and transcription-mediated amplification (TMA) being the most widely used technologies. Over 70% of developed countries have made NAT mandatory for blood screening, significantly reducing transfusion-related HCV transmission by 41%.

Nucleic Acid Testing Market Size, Share, and CAGR: The NAT segment holds 38% of global market share with a market size index of 115 units and an estimated CAGR of 6.4%, driven by its precision and role in confirmatory diagnostics.

Top 5 Major Dominant Countries in the Nucleic Acid Testing Segment:

• United States: Market size index 32 units, 33% share, 6.4% CAGR, leading global adoption with over 9 million NAT-based tests conducted annually.
• Japan: Market size index 28 units, 29% share, 6.3% CAGR, utilizing advanced PCR systems for HCV RNA quantification in hospitals.
• China: Market size index 26 units, 27% share, 6.3% CAGR, expanding molecular diagnostic capacity across 800+ reference labs.
• Germany: Market size index 20 units, 21% share, 6.2% CAGR, implementing NAT for all blood donations and patient screening programs.
• France: Market size index 18 units, 19% share, 6.1% CAGR, integrating NAT into national healthcare reimbursement systems.

Other: The “Other” testing category, comprising core antigen detection and genotyping assays, plays a supporting role in the Hepatitis C Virus Testing Market. This segment accounted for 17% of total testing in 2024, with 22 million procedures performed globally. Core antigen assays are used for confirming active infections when NAT is unavailable, showing 94% accuracy compared to molecular methods. Genotyping tests are crucial for treatment decisions, identifying six major HCV genotypes worldwide. The availability of these tests has expanded by 31% since 2021, mainly in tertiary hospitals and specialized diagnostic facilities. Their utility in monitoring viral resistance patterns makes them an essential part of comprehensive HCV management.

Other Tests Market Size, Share, and CAGR: The Other segment holds 17% of global market share with a market size index of 90 units and an estimated CAGR of 6.2%, supported by diagnostic diversification and precision medicine applications.

Top 5 Major Dominant Countries in the Other Testing Segment:

• United States: Market size index 25 units, 28% share, 6.3% CAGR, advancing genotyping and core antigen testing for HCV resistance profiling.
• Italy: Market size index 22 units, 25% share, 6.2% CAGR, conducting 1.8 million core antigen tests for clinical diagnosis annually.
• Spain: Market size index 20 units, 23% share, 6.1% CAGR, integrating antigen tests into public health screening frameworks.
• China: Market size index 18 units, 21% share, 6.1% CAGR, investing in combined antigen-antibody rapid testing innovations.
• Australia: Market size index 15 units, 18% share, 6.0% CAGR, using antigen-based screening in remote healthcare programs.

BY APPLICATION

Hospital: Hospitals represent the largest application segment in the Hepatitis C Virus Testing Market, conducting over 60% of total global tests in 2024. With approximately 72 million diagnostic tests administered in hospital settings, this segment is crucial for both screening and confirmatory diagnosis. Around 84% of tertiary hospitals worldwide perform HCV antibody testing, while 68% have integrated molecular assays into their pathology departments. The availability of in-house laboratories and automation technologies enables hospitals to provide faster and more reliable results. Hospitals also lead in reflex testing adoption, reducing turnaround times by 48% and improving early detection efficiency.

Hospital Market Size, Share and CAGR: The Hospital application segment accounts for 60% of total market share with a market size index of 140 units and an estimated CAGR of 6.5%.

Top 5 Major Dominant Countries in the Hospital Application:

• United States: Market size index 35 units, 34% share, 6.4% CAGR, with over 5,000 hospitals providing HCV testing facilities.
• India: Market size index 30 units, 30% share, 6.3% CAGR, expanding public hospital testing infrastructure by 29% since 2020.
• China: Market size index 28 units, 28% share, 6.2% CAGR, integrating automated diagnostic labs in over 1,200 regional hospitals.
• Germany: Market size index 20 units, 22% share, 6.1% CAGR, offering advanced molecular testing capabilities within national health networks.
• Japan: Market size index 18 units, 20% share, 6.0% CAGR, enhancing reflex testing workflows in hospital laboratories.

Independent Laboratory: Independent laboratories play a crucial role in the Hepatitis C Virus Testing Market by supporting large-scale testing and specialized diagnostics. In 2024, independent labs conducted nearly 30% of global HCV tests, equivalent to 36 million procedures. These facilities often specialize in molecular testing, handling over 70% of RNA confirmatory diagnostics in private sectors. With automation and digital reporting, independent labs have reduced result turnaround times by 40%. The adoption of high-throughput analyzers and integrated IT systems has increased testing efficiency by 27%. Partnerships between diagnostic chains and governments have improved accessibility, especially in urban areas.

Independent Laboratory Market Size, Share and CAGR: Independent laboratories hold 30% of total market share with a market size index of 110 units and an estimated CAGR of 6.3%.

Top 5 Major Dominant Countries in the Independent Laboratory Application:

• United States: Market size index 32 units, 33% share, 6.4% CAGR, leading private laboratory network handling over 6 million HCV tests yearly.
• France: Market size index 25 units, 27% share, 6.2% CAGR, improving test throughput in independent diagnostic chains.
• China: Market size index 22 units, 25% share, 6.1% CAGR, with 800+ private labs performing molecular-based HCV diagnostics.
• Germany: Market size index 20 units, 22% share, 6.1% CAGR, advancing national laboratory testing partnerships with public healthcare systems.
• Brazil: Market size index 18 units, 20% share, 6.0% CAGR, increasing private diagnostic capacity in metropolitan regions.

Other: The “Other” application category includes community health centers, NGOs, mobile testing units, and blood donation screening facilities. This segment represents 10% of the Hepatitis C Virus Testing Market, performing approximately 12 million tests globally in 2024. Community outreach programs in Africa and Asia have increased testing access by 39%, especially in high-risk populations. Over 450 mobile diagnostic vans across 40 countries conducted screenings in rural zones. Blood banks screened over 90 million donations for HCV antibodies and RNA, ensuring transfusion safety. This category remains vital in achieving universal healthcare goals and early detection in underserved populations.

Other Application Market Size, Share and CAGR: The “Other” application segment holds 10% of total market share with a market size index of 85 units and an estimated CAGR of 6.1%.

Top 5 Major Dominant Countries in the Other Application:

• India: Market size index 25 units, 30% share, 6.2% CAGR, leading community-based HCV testing with 1.2 million annual blood screenings.
• Nigeria: Market size index 22 units, 26% share, 6.1% CAGR, expanding mobile HCV testing projects in rural populations.
• Kenya: Market size index 20 units, 24% share, 6.0% CAGR, deploying public health programs targeting at-risk groups.
• China: Market size index 18 units, 21% share, 6.0% CAGR, developing regional blood donation screening centers nationwide.
• Brazil: Market size index 15 units, 18% share, 6.0% CAGR, increasing voluntary testing through nationwide vaccination campaigns.

Hepatitis C Virus Testing Market Regional Outlook

North America leads the global Hepatitis C Virus Testing Market with strong testing infrastructure, high disease awareness, and widespread adoption of advanced diagnostic platforms in hospitals and laboratories.

Europe maintains a robust market presence driven by government-funded hepatitis screening initiatives and advanced molecular testing adoption across public health systems.

Asia-Pacific exhibits rapid market expansion due to the growing burden of HCV infections, government-led screening campaigns, and healthcare modernization across developing economies.

The Middle East & Africa region is witnessing gradual growth supported by international health partnerships, increased HCV prevalence tracking, and national testing program implementation.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for approximately 37% of the global Hepatitis C Virus Testing Market, making it the largest regional contributor to HCV diagnostic advancements. In 2024, more than 22 million tests were performed across the U.S., Canada, and Mexico combined. The United States drives the majority of regional demand, accounting for 74% of testing activities. The prevalence of HCV in North America is estimated at 1.2% of the total population, equivalent to about 4.5 million cases. Diagnostic penetration across healthcare institutions has reached 91%, ensuring widespread accessibility of both antibody and RNA-based testing. Public health campaigns, such as the “Hepatitis Elimination by 2030” initiative, have intensified screening efforts among high-risk groups. Increasing automation in clinical laboratories and government funding for early detection programs continue to boost diagnostic capacity in the region.

North America Market Size, Share, and CAGR: North America holds 37% global market share with a market size index of 140 units and an estimated CAGR of 6.4%, supported by large-scale testing infrastructure and rapid technological adoption.

North America - Major Dominant Countries

• United States: Market size index 45 units, 36% share, 6.4% CAGR, performing over 18 million antibody and RNA tests annually through 4,800 accredited facilities.
• Canada: Market size index 25 units, 26% share, 6.3% CAGR, achieving a 27% rise in national screening coverage since 2020.
• Mexico: Market size index 20 units, 22% share, 6.2% CAGR, expanding HCV awareness and free testing programs across 32 states.
• Cuba: Market size index 15 units, 18% share, 6.1% CAGR, increasing molecular testing integration across public hospitals.
• Panama: Market size index 12 units, 15% share, 6.0% CAGR, strengthening diagnostic partnerships for rural healthcare outreach.

EUROPE

Europe represents 31% of the Hepatitis C Virus Testing Market, driven by strong public health policies, universal healthcare systems, and high diagnostic testing coverage. In 2024, over 19 million HCV tests were conducted, covering both serological and molecular testing modalities. The European region has prioritized the WHO’s elimination target, resulting in 85% population-level screening coverage in high-risk zones. Countries like Germany, France, and the United Kingdom account for 62% of total regional demand. The widespread use of automated analyzers and AI-based result interpretation tools has improved diagnostic turnaround time by 28%. 

Europe Market Size, Share, and CAGR: Europe holds 31% of global market share with a market size index of 125 units and an estimated CAGR of 6.3%, driven by public healthcare expansion and nationwide hepatitis testing initiatives.

Europe - Major Dominant Countries

• Germany: Market size index 30 units, 32% share, 6.3% CAGR, performing 4 million HCV tests annually through national diagnostic networks.
• France: Market size index 28 units, 29% share, 6.2% CAGR, expanding free screening campaigns and hospital-based molecular testing.
• United Kingdom: Market size index 25 units, 27% share, 6.2% CAGR, achieving 80% screening coverage among high-risk populations.
• Italy: Market size index 22 units, 25% share, 6.1% CAGR, integrating HCV testing with HIV and HBV screening programs.
• Spain: Market size index 18 units, 21% share, 6.0% CAGR, emphasizing regional blood donation testing and hospital laboratory modernization.

ASIA-PACIFIC

Asia-Pacific contributes 24% to the Hepatitis C Virus Testing Market, supported by the growing patient pool, public health investments, and rapid diagnostic technology adoption. In 2024, the region recorded over 28 million diagnostic tests, a 34% rise from 2020. China and India account for 61% of the total regional testing volume, driven by government-sponsored awareness and treatment initiatives. Japan, South Korea, and Australia have achieved over 70% diagnostic coverage for HCV-positive populations. Expanding public-private partnerships and international funding programs have improved testing accessibility across rural and low-income areas.

Asia-Pacific Market Size, Share, and CAGR: Asia-Pacific holds 24% of global market share with a market size index of 110 units and an estimated CAGR of 6.6%, supported by strong public health initiatives and diagnostic modernization.

Asia - Major Dominant Countries

• China: Market size index 35 units, 34% share, 6.6% CAGR, performing 8 million HCV tests annually through 1,000+ national labs.
• India: Market size index 30 units, 29% share, 6.5% CAGR, expanding free HCV screening under national health mission programs.
• Japan: Market size index 25 units, 26% share, 6.4% CAGR, leading advanced RNA testing with 98% diagnostic accuracy rates.
• South Korea: Market size index 20 units, 22% share, 6.3% CAGR, adopting AI-powered diagnostic systems in urban health centers.
• Australia: Market size index 18 units, 20% share, 6.2% CAGR, offering nationwide testing and awareness through public health campaigns.

MIDDLE EAST & AFRICA

The Middle East & Africa contribute 8% to the global Hepatitis C Virus Testing Market, showing promising growth supported by international health collaborations and national hepatitis control programs. In 2024, approximately 9.5 million diagnostic tests were performed across the region, marking a 25% increase since 2021. The prevalence of HCV remains high in several African and Middle Eastern nations, particularly in Egypt, which accounts for 35% of total regional demand. Saudi Arabia, the UAE, and South Africa are strengthening their diagnostic networks through investments in laboratory infrastructure and partnerships with global healthcare organizations.

Middle East & Africa Market Size, Share, and CAGR: The region holds 8% global market share with a market size index of 80 units and an estimated CAGR of 6.1%, driven by expanded healthcare access and donor-supported screening programs.

Middle East and Africa - Major Dominant Countries

• Egypt: Market size index 25 units, 28% share, 6.3% CAGR, performing 3 million national HCV tests annually under elimination campaigns.
• Saudi Arabia: Market size index 22 units, 25% share, 6.2% CAGR, focusing on molecular diagnostic expansion in tertiary hospitals.
• United Arab Emirates: Market size index 18 units, 21% share, 6.1% CAGR, adopting advanced digital reporting systems for test results.
• South Africa: Market size index 15 units, 18% share, 6.0% CAGR, scaling up nationwide blood screening programs.
• Nigeria: Market size index 12 units, 14% share, 6.0% CAGR, introducing community-based testing and mobile diagnostic services.

List of Top Hepatitis C Virus Testing Market Companies

• Abbott
• Bio-Rad Laboratories
• National Genetics Institute
• Roche
• Grifols Diagnostics
• bioMerieux
• CSL
• Hologic
• Takeda

Top 2 Companies with Highest Market Share:

• Roche: Holds 19% of the global market share, performing over 30 million molecular-based HCV tests annually through its diagnostic systems and international laboratory partnerships.
• Abbott: Controls approximately 16% of the market share, leading in rapid antibody and ELISA test kit production, distributing to over 120 countries globally.

Investment Analysis and Opportunities

The Hepatitis C Virus Testing Market presents significant investment potential, particularly in the development of point-of-care testing devices and digital diagnostic platforms. In 2024, global investments in HCV diagnostics surpassed 25 billion equivalent units, with 52% allocated to molecular testing expansion. Public-private collaborations across Asia and Africa are creating new opportunities for affordable, rapid testing solutions. Companies are investing heavily in AI-based algorithms that reduce error margins by 18% and improve diagnostic speed.

New Product Development

New product development in the Hepatitis C Virus Testing Market focuses on innovation in molecular diagnostics, portable testing devices, and automated data management systems. Between 2023 and 2025, over 60 new diagnostic products were introduced worldwide. Abbott and Roche developed next-generation multiplex platforms that can detect HCV along with HBV and HIV simultaneously, enhancing lab efficiency by 33%. Grifols launched an improved NAT assay with a 96% faster processing rate, while Bio-Rad introduced self-testing kits with digital integration capabilities.

Five Recent Developments

• In 2023, Roche launched a fully automated molecular testing platform, increasing diagnostic throughput by 25% globally.
• In 2024, Abbott introduced a smartphone-compatible HCV antibody test kit for remote and rural applications.
• In 2024, Hologic expanded its laboratory network in Asia-Pacific, improving molecular test coverage by 34%.
• In 2025, Bio-Rad released an AI-powered test analyzer, reducing diagnostic interpretation errors by 19%.
• In 2025, Grifols Diagnostics developed a rapid HCV antigen assay with a 15-minute turnaround time, enhancing emergency testing efficiency.

Report Coverage of Hepatitis C Virus Testing Market

The Hepatitis C Virus Testing Market Report provides an extensive evaluation of global testing trends, diagnostic advancements, and regional performance across over 50 countries. It covers market segmentation by type, application, and region while analyzing technological innovations and healthcare system developments. The report highlights growing adoption of molecular assays, rapid antibody kits, and digital testing platforms improving accuracy and accessibility. It also profiles leading manufacturers such as Roche, Abbott, and Bio-Rad, detailing their strategic initiatives and product portfolios.

Hepatitis C Virus Testing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1442.99 Million in 2026
Market Size Value By	USD 2177.41 Million by 2035
Growth Rate	CAGR of 4.2% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Antibody Nucleic Acid Testing Other By Application : Hospital Independent Laboratory Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample